<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="publisher">pbio</journal-id><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="pmc">plosbiol</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="doi">10.1371/journal.pmed.0030117</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Correspondence</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Biochemistry/Drug Discovery</subject>
          <subject>Mental Health</subject>
          <subject>Mental Health</subject>
        </subj-group>
        <subj-group subj-group-type="System Taxonomy">
          <subject>Anxiety disorders (including obsessive compulsive disorder and post-traumatic stress disorder)</subject>
          <subject>Drugs and adverse drug reactions</subject>
          <subject>Mood disorders (including depression)</subject>
          <subject>Psychiatry</subject>
        </subj-group>
      </article-categories><title-group><article-title>Why Did the FDA Approve These Advertisements?</article-title><alt-title alt-title-type="running-head">Correspondence</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Oaks</surname>
            <given-names>David</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1">
				<label>1</label>
				
				<addr-line>MindFreedom International Eugene, Oregon, United States of America</addr-line>
				
			</aff><author-notes>
        <corresp id="cor1">* To whom correspondence should be addressed. E-mail: <email xlink:type="simple">oaks@mindfreedom.org</email></corresp>
      <fn fn-type="conflict" id="n2">
        <p>
					 DO directs MindFreedom International, a nonprofit human rights organization. We are pro-choice on psychiatric drugs, and many of our members choose to take prescribed psychiatric drugs. However, we have engaged in protests of what we perceive as the psychiatric drug industry's unfair dominance of the mental health system.
				</p>
      </fn></author-notes><pub-date pub-type="ppub">
        <month>2</month>
        <year>2006</year>
      </pub-date><pub-date pub-type="epub">
        <day>28</day>
        <month>2</month>
        <year>2006</year>
      </pub-date><volume>3</volume><issue>2</issue><elocation-id>e117</elocation-id><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2006</copyright-year><copyright-holder>David Oaks</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article page="e392" related-article-type="companion" vol="3" xlink:href="info:doi/10.1371/journal.pmed.0020392" xlink:title="essay" xlink:type="simple">
				<article-title>Serotonin and Depression: A Disconnect between the Advertisements and the Scientific Literature</article-title>
			</related-article></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title/>
      <p>I would like to thank 
				<italic>PLoS Medicine</italic> for publishing Lacasse and Leo's important and methodical Essay that debunks the “chemical imbalance” advertisements for psychiatric drugs [<xref ref-type="bibr" rid="pmed-0030117-b1">1</xref>]. Why would the United States Food and Drug Administration (FDA) approve such ads? Our human rights group, MindFreedom International, has been asking that question for a long time. On behalf of MindFreedom, US Senator Ron Wyden contacted the FDA for an explanation about why they approve such advertising. In their response—which took over one year to receive—the FDA could cite no scientific literature or studies. It turns out there's a good reason that the FDA can't find any scientific evidence for the claims of a “chemical imbalance” in these ads: the scientific evidence in support of the serotonin hypothesis is very weak.
			</p>
      <p>Readers who would like more information about the psychiatric industry's advertising suggesting a “chemical imbalance” in depression may be interested in the following: (1) MindFreedom's debate with Pfizer, manufacturer of Zoloft, available at 
				<ext-link ext-link-type="uri" xlink:href="http://www.mindfreedom.org/mindfreedom/pfizerlies.shtml" xlink:type="simple">http://www.mindfreedom.org/mindfreedom/pfizerlies.shtml</ext-link>, and (2) a historic debate with the American Psychiatric Association resulting from MindFreedom's 2003 hunger strike, available at 
				<ext-link ext-link-type="uri" xlink:href="http://www.mindfreedom.org/mindfreedom/hungerstrike.shtml" xlink:type="simple">http://www.mindfreedom.org/mindfreedom/hungerstrike.shtml</ext-link> (Researcher Jonathan Leo was on the MindFreedom International Scientific Panel for the hunger strike).
			</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="pmed-0030117-b1">
        <label>1</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Lacasse</surname>
              <given-names>JR</given-names>
            </name>
            <name name-style="western">
              <surname>Leo</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Serotonin and depression: A disconnect between the advertisements and the scientific literature.</article-title>
          <source>PLoS Med</source>
          <year>2005</year>
          <volume>2</volume>
          <fpage>e392</fpage>
          <comment>doi: <ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0020392" xlink:type="simple">10.1371/journal.pmed.0020392</ext-link></comment>
        </nlm-citation>
      </ref>
    </ref-list>
    
  </back>
</article>